Recent news coverage includes general market and sector-related articles with limited direct updates on Oncology Institute, Inc. Notably, the company was highlighted for strong Q4 results and focus on 2026 profitability in March 2026.

• The Oncology Institute reported strong Q4 results and indicated focus on 2026 profitability as of March 13, 2026 [N8].
• Recent news coverage includes broader market and sector developments such as Alphabet's investment in Malaysia data centers [N1], and energy sector updates [N3][N4][N8].

TOI's business model leverages the growing shift toward value-based care in oncology, with a large and expanding patient population under capitated and full delegation contracts. The company's integrated care approach, combining medical oncology, radiation therapy, specialty pharmacy, and clinical trials, positions it to deliver comprehensive, evidence-based care in convenient community settings. TOI's technology platform and clinical data-driven protocols support scalable and consistent care delivery. The company's strong payor relationships and experience managing risk-bearing contracts may enable continued growth in value-based arrangements. Increasing specialty pharmacy volumes and expanding clinical trial services contribute to diversified revenue streams. The company's focus on reducing wasteful care and improving patient outcomes aligns with payor and patient interests, potentially enhancing its market position.

TOI faces risks related to the complexity of managing value-based contracts, including capitation and full delegation arrangements, which require effective cost control and quality management to maintain profitability. The company's net losses and negative earnings per share as of September 30, 2026 indicate ongoing challenges in achieving profitability. Changes in payor reimbursement policies, regulatory environments, or healthcare legislation could adversely affect revenue and contract terms. The reliance on affiliated physician-owned professional corporations and independent providers introduces operational and compliance risks, including adherence to corporate practice of medicine laws and contractual restrictions. Competition from other oncology providers and shifts in referral patterns may impact fee-for-service volumes. Additionally, liquidity constraints indicated by limited cash and equivalents relative to current liabilities could pose financial risks.

TOI's moat is based on its established network of affiliated physician-owned professional corporations and independent providers across multiple states, enabling scale in value-based oncology care. The company's long-standing relationships with payors and experience managing capitated and full delegation contracts provide competitive advantages in risk management and care coordination. TOI's comprehensive care model integrates medical oncology, radiation therapy, specialty pharmacy, and clinical trials in community settings, differentiating it from traditional academic or tertiary care providers. The company's adherence to evidence-based clinical pathways aligned with NCCN guidelines and its technology platform for standardized care delivery support consistent quality and cost management. Additionally, contractual arrangements such as management services agreements and stock transfer restrictions help maintain operational control and alignment with affiliated physicians. These factors collectively create barriers to entry and support TOI's position in the value-based oncology market.

• Contractual and Operational Complexity: Managing multiple forms of value-based contracts, including capitation, gain/loss sharing, and full delegation, requires sophisticated operational capabilities and risk management to control costs and meet quality metrics.
• Profitability Challenges: The company reported net losses and negative earnings per share for the quarter ended September 30, 2026, indicating ongoing challenges in achieving sustainable profitability.
• Regulatory and Compliance Risks: Compliance with corporate practice of medicine laws and maintaining contractual restrictions with affiliated physician practices pose legal and operational risks.
• Payor and Reimbursement Risks: Changes in reimbursement policies, payor contract terms, or healthcare regulations could adversely impact revenue streams and contract profitability.
• Competitive and Referral Risks: Dependence on referrals for fee-for-service patients and competition from other oncology providers may affect patient volumes and revenue.
• Liquidity and Financial Risks: Limited cash and equivalents relative to current liabilities and ongoing losses may constrain financial flexibility and operational capacity.

• Oncology Institute, Inc. (TOI) is a value-based oncology company managing community-based oncology practices across 17 markets and five states in the U.S. as of September 30, 2026.
• TOI operates 67 community-based oncology practices staffed with 125 oncologists and advanced practice providers employed by affiliated physician-owned professional corporations (Starling PCs).
• TOI manages a population of approximately 2.2 million patients under value-based agreements as of September 30, 2026.
• The company provides medical oncology services including physician services, in-house infusion, specialty pharmacy, clinical trials, radiation therapy, educational seminars, support groups, counseling, and 24/7 patient assistance.
• TOI's business model includes fee-for-service (FFS) revenue, capitation revenue under value-based contracts, specialty pharmacy revenue, and clinical trials revenue.
• Capitation revenue is paid monthly based on per member per month (PMPM) fees from managed care organizations, with contracts generally lasting one year or longer.
• FFS revenue is earned from specific medical services billed and collected for services rendered by Starling PCs' employed physicians, dependent on referrals from other physicians.
• Specialty pharmacy operates through physician dispensaries providing oral oncology and related medications, with revenue based on fee schedules set by pharmacy benefit managers and other payors.
• Clinical trials revenue is generated through contracts to perform clinical research trials, with payments based on administrative fees, patient site visits, and expense reimbursements.
• TOI entered a profit sharing arrangement with Helios Clinical Research in 2025 for clinical trials operations.
• The company focuses on value-based care to deliver better quality and lower cost oncology care by reducing wasteful or inefficient care.
• TOI's care model emphasizes adherence to National Comprehensive Cancer Network (NCCN) guidelines and evidence-based treatment protocols.
• The company operates under management services agreements with affiliated physician-owned professional corporations, providing non-medical operational services and receiving fees based on gross revenues.
• As of September 30, 2026, TOI's financial snapshot shows cash and equivalents of $200,000, current assets of $137.69 million, current liabilities of $123.7 million, a current ratio of 1.11, and a net loss of $15.748 million for the quarter ending September 30, 2026.
• Earnings per share basic and diluted were both -$0.13 for the quarter ended September 30, 2026.
• Revenue for the three months ended September 30, 2026 was $169.767 million, a 24.3% increase from the prior year period, driven by a 40% increase in capitated revenue and a 44% increase in specialty pharmacy revenue.
• Operating expenses increased 19.5% for the three months ended September 30, 2026 compared to the prior year period, with increases in clinical payroll costs and network medical expenses.
• Selling, general and administrative expenses increased 27.2% for the three months ended September 30, 2026 compared to the prior year period.
• The company emphasizes delivering oncology care in community settings rather than academic or tertiary care centers.
• TOI's value-based contracts include capitation, gain/loss sharing, and full delegation contracts, allowing control over outpatient oncology treatment and risk management.
• The company manages both affiliated clinics and a network of independent providers under value-based contracts.
• TOI's mission is to provide optimal health outcomes and healthcare affordability through value-based care, aligning incentives with payors and patients.
• The company uses technology platforms to standardize and deliver consistent value-based care at scale.
• TOI's affiliated providers are not incentivized to over-treat and focus on evidence-based oncology care.
• The company has contractual relationships with payors including Medicare Advantage, Medicaid, and commercial insurers.
• TOI's clinical trials and palliative care services are traditionally accessed through academic settings but are provided in community clinics by TOI PCs.
• The company has stock transfer restriction agreements with physician shareholders of affiliated professional corporations to maintain control and compliance.
• TOI's liquidity ratios as of September 30, 2026 include a current ratio of 1.11 and a cash ratio of 0, indicating current assets slightly exceed current liabilities but limited cash liquidity.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.